RESUMEN
BACKGROUND: The impact of neurorehabilitation on patients with prolonged disorders of consciousness (PDOC) is not well known. We assessed the range of motion (ROM), muscle girth and power, level of consciousness, development of musculoskeletal deformity, and superficial sensation. METHODS: A retrospective observational record-based study was done, which included the data of patients diagnosed with PDOC admitted at Thumbay Physical Therapy & Rehabilitation Hospital, Ajman, UAE, between 2020 and 2022. Data on the "range of motion", "muscle girth and power", "level of consciousness", "development of musculoskeletal deformity", and "superficial sensation" were collected and analyzed. The SPSS software version 27 (IBM Corp., Armonk, NY, USA) was used for analysis. The chi-square test was used to assess association, and the t-test was used to test the mean difference. RESULTS: We assessed the data of 21 patients with PDOC. The superficial sensation was found to have increased significantly (p<0.025). There was a decrease in the proportion of patients with musculoskeletal deformities during the follow-up period. The ROM, muscle girth, and muscle power were also preserved without significant deterioration. However, the level of consciousness measured by the Glasgow coma scale (GCS) showed no improvement. CONCLUSIONS: Our research showed that neurorehabilitation significantly improves superficial sensation and prevents the development of musculoskeletal deformities. However, the mean level of consciousness remained the same. There was also no decrease in ROM. Both muscle girth and power were preserved over two years.
RESUMEN
BACKGROUND: Shiga toxin-producing Escherichia coli (STEC) is a major source of food-borne illness around the world. E. coli O157 has been widely reported as the most common STEC serogroup and has emerged as an important enteric pathogen. Cattle, in particular have been identified as a major E. coli O157:H7 reservoir of human infections; however, the prevalence of this organism in camels, sheep, and goats is less understood. The aim of this study was to evaluate the occurrence and concentration of E. coli serotype O157 in the feces of healthy camels (n = 140), cattle (n = 137), sheep (n = 141) and goats (n = 150) slaughtered in United Arab Emirates (UAE) for meat consumption between September 2017 and August 2018. We used immunomagnetic separation coupled with a culture-plating method to detect E. coli O157. Non-sorbitol fermenting colonies were assessed via latex-agglutination testing, and positive cultures were analyzed by performing polymerase chain reactions to detect genes encoding attaching and effacing protein (eaeA), hemolysin A (hlyA, also known as ehxA) and Shiga toxin (stx1 and stx2), and E. coli O157:H7 specific genes (rfb O157, uidA, and fliC). All E. coli O157 isolates were analyzed for their susceptibility to 20 selected antimicrobials. RESULTS: E. coli O157 was observed in camels, goats, and cattle fecal samples at abundances of 4.3, 2, and 1.46%, respectively, but it was undetectable in sheep feces. The most prevalent E. coli O157 gene in all STEC isolates was stx2;, whereas, stx1 was not detected in any of the samples. The fecal samples from camels, goats, and cattle harbored E. coli O157 isolates that were 100% susceptible to cefotaxime, chloramphenicol, ciprofloxacin, norfloxacin, and polymyxin B. CONCLUSION: To our knowledge, this is the first report on the occurrence of E. coli O157 in slaughter animals in the UAE. Our results clearly demonstrate the presence of E. coli O157 in slaughtered animals, which could possibly contaminate meat products intended for human consumption.
Asunto(s)
Antibacterianos/farmacología , Infecciones por Escherichia coli/epidemiología , Rumiantes/microbiología , Escherichia coli Shiga-Toxigénica/efectos de los fármacos , Escherichia coli Shiga-Toxigénica/patogenicidad , Factores de Virulencia/genética , Animales , Camelus/microbiología , Bovinos , Cefotaxima/farmacología , Cloranfenicol/farmacología , Ciprofloxacina/farmacología , Infecciones por Escherichia coli/veterinaria , Proteínas de Escherichia coli/genética , Heces/microbiología , Femenino , Microbiología de Alimentos , Cabras , Masculino , Pruebas de Sensibilidad Microbiana , Norfloxacino/farmacología , Polimixina B/farmacología , Prevalencia , Ovinos , Escherichia coli Shiga-Toxigénica/clasificación , Escherichia coli Shiga-Toxigénica/genética , Emiratos Árabes Unidos/epidemiologíaRESUMEN
Escherichia coli O157:H7 is a common food pathogen which has a serious effect on human health. We report here the complete genome sequence of Escherichia coli O157:H7 strain Al Ain, isolated from camel feces in the United Arab Emirates.
RESUMEN
In this study the effect of Helicteres isora L. on erythrocyte membrane bound enzymes and antioxidants activity in plasma and erythrocytes of streptozotocin (STZ) induced diabetic model was investigated. The aqueous bark extract of H. isora was administered orally for 30 days to control and STZ induced diabetic rats. The effect of bark extract on glucose, insulin, haemoglobin, glycosylated haemoglobin, TBARS, hydroperoxide, superoxide dismutase (SOD), catalase (CAT), glutathione peroxide (GPx), glutathione-S-transferase (GST), vitamins C and E, reduced glutathione (GSH) and membrane bound enzymes were studied. The levels of glucose, glycosylated haemoglobin, TBARS, hydroperoxide, and vitamin E were increased significantly whereas the level of insulin, haemoglobin, as well as antioxidants, membrane bound total ATPase, Na(+)/K(+)-ATPase, Ca(2+)-ATPase and Mg(2+)-ATPase were decreased significantly in STZ diabetic rats. Administration of bark extract to diabetic rats showed a decrease in the levels of glucose, glycosylated haemoglobin, lipid peroxidation markers and vitamin E. In addition the levels of insulin, haemoglobin, enzymatic antioxidants, vitamin C, and GSH and the activities of membrane bound enzymes also were increased in H. isora treated diabetic rats. The present study indicates that the H. isora possesses a significant favourable effect on erythrocyte membrane bound enzymes and antioxidants defense system in addition to its antidiabetic effect.
Asunto(s)
Antioxidantes/metabolismo , Diabetes Mellitus Experimental/tratamiento farmacológico , Membrana Eritrocítica/efectos de los fármacos , Hipoglucemiantes/farmacología , Malvaceae/química , Fitoterapia , Adenosina Trifosfatasas/sangre , Adenosina Trifosfatasas/metabolismo , Animales , Glucemia/metabolismo , Diabetes Mellitus Experimental/sangre , Membrana Eritrocítica/enzimología , Hemoglobina Glucada/metabolismo , Hemoglobinas/metabolismo , Insulina/sangre , Metabolismo de los Lípidos/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Masculino , Corteza de la Planta/química , Extractos Vegetales/farmacología , Ratas , Ratas Wistar , Tolbutamida/farmacologíaRESUMEN
The aim of the present study was to evaluate the effect of aqueous bark extract of Helicteres isora (HI) (Sterculiaceae) on the blood glucose, plasma insulin and fatty acid composition of the total lipids in the liver, kidney and brain of control and streptozotocin (STZ) diabetic rats. The analysis of fatty acids showed that there was a significant increase in the concentrations of palmitic acid (16:1), stearic acid (18:0) and oleic acid (18:1) in the liver, kidney and brain, whereas the concentrations of linolenic acid (18:3) and arachidonic acid (20:4) were significantly decreased in STZ diabetic rats. Oral administration of the aqueous bark extract of HI (100, 200mg/kg body weight) for 30 days to diabetic rats decreased the concentrations of fatty acids, viz., palmitic, stearic, and oleic acid, whereas linolenic and arachidonic acid were elevated. These results suggest that HI exhibits antidiabetic and antihyperlipidemic effects in STZ induced diabetic rats. It also prevents the fatty acid changes produced during diabetes. The antidiabetic and antihyperlipidemic effects of HI are more potent than those of tolbutamide, as standard drug. The results of the present study indicate that HI showed an antihyperlipidemic effect in addition to its antidiabetic effect in type 2 diabetic rats.